Narrative review / 2022
A scoping review found insufficient evidence that high plasma vitamin B12 or B12 intake is causally related to cancer.
A systematic literature search and scoping review of human studies (January 2005–March 2022) examined the relationship between vitamin B12 biomarkers, intake, and cancer. Except for liver cancer, associations between plasma vitamin B12 and cancer were inconsistent across studies, and intake from food or supplements was even less consistent. There was no evidence for temporality, coherence, or a biologically meaningful dose-response relationship, though genetically determined high plasma B12 was likely associated with cancer. The authors concluded there is insufficient evidence that high plasma vitamin B12, high intake, or pharmacological doses are causally related to cancer.
- Study type
- Scoping review
- Who was studied
- Human studies published in PubMed between January 2005 and March 2022
- What was measured
- Association and causality between vitamin B12 and cancer
THE PAPER
High Plasma Vitamin B12 and Cancer in Human Studies: A Scoping Review to Judge Causality and Alternative Explanations.
Obeid R. Nutrients, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.